10x Genomics Beats Q3 2026 Estimates as Revenue Rises 1.1% to $150.7M
Revenue of $150.7M vs. $148.0M expected and adjusted EPS of -$0.15 vs. -$0.27; revenue up 1.1% from a year earlier.
10x Genomics (TXG) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $150.7 million, up 1.1% from a year earlier, above the $148.0 million estimate, and adjusted EPS was -$0.15, up 32% from a year earlier, above the -$0.27 estimate.
Shares rose 3.3% in after-hours trading as of 4:06 p.m. ET, to $59.99 from a $58.06 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | -$0.27 | -$0.15 | Beat by 44% |
| Revenue | $148.0M | $150.7M | Beat by 1.8% |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▲ 32% | ▼ 7.1% |
| Revenue | ▲ 1.1% | ▼ 0.2% |
By our calculation, revenue was $2.7 million above the estimate and adjusted EPS was $0.12 above it. The QoQ column compares with the previous quarter's revenue of $151.0 million and adjusted EPS of -$0.14. The YoY column compares with $149.0 million and -$0.22 in the same quarter a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 6 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 7 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $149.0 million, $166.0 million, $150.8 million, $151.0 million and $150.7 million.
What to watch
- Next-quarter estimates. Consensus calls for EPS of -$0.23 and revenue of $171.4 million next quarter, based on 3 analysts.
- Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 1.1% increase to $150.7 million.
- Estimate record. Whether 10x Genomics extends a record of beating EPS estimates in 6 of its last 8 reports.
- Related coverage. See our reports on Tandem Diabetes Care, Savers Value Village, Opendoor and Natera.
Sources: Results are from 10x Genomics's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from 10x Genomics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Tandem Diabetes Care Beats Q3 2026 Estimates as Revenue Rises 14% to $283.7M
EarningsSavers Value Village Beats Q3 2026 Estimates as Revenue Rises 8.5% to $463.1M
EarningsOpendoor Misses Q3 2026 Estimates as Revenue Rises 12% to $1.02B
EarningsNatera Q3 2026 Revenue Tops Estimates at $794.0M, but EPS Misses at -$0.42
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.